^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NACC2-NTRK2 fusion

    i
    Other names: NACC2, NACC Family Member 2, NACC Family Member 2, BEN And BTB (POZ) Domain Containing, Repressor With BTB Domain And BEN Domain, Nucleus Accumbens-Associated Protein 2, BTB/POZ Domain-Containing Protein 14A, BTB (POZ) Domain Containing 14A, BEN Domain Containing 9, BTBD14A, BTBD31, BEND9, NAC-2, RBB, Transcription Repressor With A BTB Domain And A BEN Domain, MGC23427, BTBD14, NAC2, NTRK2, TRKB, Neurotrophic tyrosine kinase, receptor, type 2
    Entrez ID:
    4915; 138151
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    3years
    Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing. (PubMed, Pathology)
    In contrast to other cancers, pan-TRK IHC appears of limited interest in this field because there is no 'on/off' IHC positivity criterion to distinguish between NTRK-rearranged and non-NTRK-rearranged gliomas. RNA sequencing analyses are necessary in FISH positive cases with less than 30% positive nuclei, to avoid false positivity when scoring is close to the detection threshold.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • LMNA (Lamin A/C) • NTRK (Neurotrophic receptor tyrosine kinase) • NACC2 (NACC Family Member 2) • PRKAR1A (Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha)
    |
    NTRK1 fusion • NTRK2 fusion • NACC2-NTRK2 fusion • NTRK fusion
    |
    VENTANA pan-TRK (EPR17341) Assay